VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Since 2017, several chimeric antigen receptor (CAR) T-cell therapies have been approved and have demonstrated excellent therapeutic efficacy in haematologic malignancies. All of the currently ...

Kamdar has now begun a new trial to study why CAR T-cell therapies aren’t effective in all patients, and whether adapting the treatment could improve outcomes. The FDA-approved CAR T cells ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

DUBLIN--(BUSINESS WIRE)--The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This report provides ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood ...

Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

Although CAR T cells have made their claim to fame in treating leukemia and lymphoma, scientists have now shown they can be directed toward other conditions. Systemic lupus erythematosus is an ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This report ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...